Pharmaceuticals News and Research

RSS

Merck introduces new products for separation and analysis at Pittcon 2016

Merck, a leading science and technology company is launching a range of new products for separation and analysis at the Pittcon Conference and Expo 2016 in Atlanta, Georgia, March 6 - 10, the world's largest conference for laboratory science.

8 Mar 2016

Pittcon 2016: Bruker showcases new products and analytical solutions

This week at Pittcon 2016, Bruker is showcasing new products and analytical solutions for core Applied & Pharma markets, for our Nanoanalysis, Microscopy & Advanced Materials Research markets, as well as new after-market services and life-cycle support solutions for our customers.

From Bruker BioSpin Division 8 Mar 2016

ACGT awards new research grants to take researchers to next level in cancer treatment

Alliance for Cancer Gene Therapy, the nation's only nonprofit dedicated exclusively to cell and gene therapies for cancer, is delighted to announce the recipients of its 2016 ACGT Young Investigator Grants.

8 Mar 2016

Xencor begins XmAb5871 Phase 2 trials in patients with IgG4-RD and Systemic Lupus Erythematosus

Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced dosing the first patient in a Phase 2 trial of XmAb5871 in patients with IgG4-Related Disease (IgG4-RD).

8 Mar 2016

Complex biomarker tests for molecularly targeted therapies lack evidentiary standards

Potentially useful biomarker tests for molecularly targeted therapies are not being adopted appropriately into clinical practice because of a lack of common evidentiary standards necessary for regulatory, reimbursement, and treatment decisions.

7 Mar 2016

U-M researchers develop novel mouse model of children's brain cancer

Children with brain cancer may soon get some help from mice with the same disease, thanks to new research from University of Michigan Medical School scientists and their colleagues.

3 Mar 2016

Researchers find Achilles' heel of acute lymphoblastic leukemia

Researchers at The Ottawa Hospital and the University of Ottawa have found the Achilles' heel of one of the most aggressive forms of leukemia that affects both children and adults. They have also identified a possible new treatment that exploits this fatal weakness.

2 Mar 2016

Inhibitors that activate brown fat may help treat diabetes, metabolic disorders

In recent decades, obesity has become a global problem. The disease goes hand in hand with a dramatic increase in the proportion of body fat. Researchers from the Max Planck Institute for Metabolism Research and the Cologne Cluster of Excellence in Cellular Stress Responses in Aging-associated Diseases at the University of Cologne have now succeeded in inhibiting a protein in mice that hampers activation of the useful "brown fat" in obese mice. When treated with inhibitors against this protein, obese mice exhibited a notable improvement of their glucose metabolism.

2 Mar 2016

Blueberry Therapeutics set to create safe, effective nanomedicines to tackle unmet healthcare needs

Blueberry Therapeutics Ltd, a leading pharmaceutical company focused on the major medical problems of inflammation and infection, are exploring the anti-microbial agenda through the development of new anti-fungal drugs and treatments to tackle this important unmet healthcare need.

2 Mar 2016

How can electronic ink help patients? An interview with Giovanni Mancini

Electronic ink is basically what the name says. It's made of ink, the same ink particles that you see on a printed paper that comes out of an inkjet printer. We use black and white pigments that we add certain properties to that allow us to move the pigments around.

2 Mar 2016

Omalizumab drug can be better targeted to treat people with severe asthma

Around five million people in the UK are currently being treated for asthma. Of these, a quarter of a million are unable to get good control of their condition, resulting in frequent, severe, or even life-threatening attacks. A new study brings hope to these patients by investigating whether the drug Omalizumab can be better targeted.

2 Mar 2016

Beta blockers may improve effectiveness of triple negative breast cancer treatments

New research published in the March 2016 issue of The FASEB Journal, shows that a commonly prescribed class of high blood pressure drugs may have the potential to slow the growth of triple negative breast cancer tumors. These drugs, called "beta blockers" work by counteracting the pro-growth effect caused by adrenaline by affecting the the beta2-adrenoceptor.

2 Mar 2016

Stemina developing new screening method to diagnose autism

A University of Wisconsin-Madison spinoff is screening blood samples in an effort to develop a biologically based method to diagnose autism.

2 Mar 2016

Preventing the spread of Zika: an interview with Professor John Oxford

The link between the Zika virus and Guillain-Barré on the one hand, and pregnancy and the virus affecting the fetus in terms of microcephaly on the other, is still not confirmed conclusively.

1 Mar 2016

Janssen ranked among 100 Best Companies to Work for in the UK

Janssen, a pharmaceutical company of Johnson & Johnson, is celebrating being ranked number 30 out of 100 Best Companies to Work for and being awarded the highest three star Best Companies Accreditation in research conducted by Best Companies in the UK and published by the Sunday Times.

1 Mar 2016

New combination treatment shows promise for treating acute myeloid leukaemia

Walter and Eliza Hall Institute researchers have discovered that the treatment of the most deadly form of blood cancer may be improved by combining two recently developed drugs.

1 Mar 2016

Rare disease day focuses on new approach to finding treatment

2,200 babies will be born in the UK on 29th February, of which 30 will die of a rare disease before they are five years old.

29 Feb 2016

New report explores strategies involved in developing and commercializing FDC products

Fixed dose combination (FDC) products, which have been around for many years, can have both clinical and commercial advantages. Successful FDC products require thoughtful planning, beginning early in the product development and lifecycle management processes.

27 Feb 2016

Novel therapeutic approach to target monomeric Tau protein

Dementia and other tauopathies, most notably Alzheimer's disease, embody a class of neurodegenerative diseases associated with the aggregation of the Tau protein in the human brain. These diseases represent one of the leading causes of death and disability in the elderly population in the western world, with no current effective therapy.

27 Feb 2016

New drug shows promise against Huntington's disease

A drug that would be the first to target the cause of Huntington's disease (HD) is effective and safe when tested in mice and monkeys, according to data released today that will be presented at the American Academy of Neurology's 68th Annual Meeting in Vancouver, Canada, April 15 to 21, 2016.

27 Feb 2016